Branded anti-infective medicines with clinically practical dosing for hospital, retail, and pediatric care.
info@anchoragepharma.com +234 808 900 0041 +234 808 900 0042
Product Profile

Anchorage Branded Anti-Infective Portfolio

Featuring CLOVERAGE, CLOVAXAN, ANCHORAGE , EFIXIM , and CLAVIXIM , this portfolio supports resistance-aware treatment, pediatric precision dosing, and dependable frontline use.

Home / Product Portfolio
Portfolio Focus

Five Core Brands Across Adult, Pediatric, and Neonatal Use

Product information here follows your profile naming exactly and is organized by pack presentation, mechanism of action, and high-priority indication clusters for prescribers and procurement teams.

5

Named Anchorage product brands

12+

Pack-size and strength variants

3-Tier

Adult, pediatric, and neonatal fit

Anchorage team preparing anti-infective medicines
Coverage includes immediate-release tablets, dispersible tablets, oral suspensions, and neonatal drops for real-world administration flexibility across care levels.
Flagship Brands

Branded Packs, Mechanisms, and Clinical Use Paths

Each card combines label-accurate pack naming with concise therapeutic positioning.

CLOVERAGE 625 drug pack

CLOVERAGE

Beta-Lactamase Protected

Dosage Forms: CLOVERAGE 625, CLOVERAGE 1000 tablets; CLOVERAGE 228.5 and CLOVERAGE 457 oral suspension.

Mechanism: Amoxicillin inhibits cell wall synthesis while Clavulanic Acid blocks beta-lactamase degradation.

  • High-value option for mixed-pathogen and resistance-pressure cases
  • Clinically trusted for both outpatient and inpatient anti-infective needs
  • Primary use across RTIs, UTIs, and skin or soft tissue infection workflows
CLOVAXAN DT 125 drug pack

CLOVAXAN

Patient-Friendly Dosing

Dosage Forms: CLOVAXAN DT 125, CLOVAXAN DT 250, CLOVAXAN 500, and CLOVAXAN 125 suspension.

Mechanism: Penicillin-class inhibition of peptidoglycan cross-linking, leading to bacterial cell lysis.

  • Dispersible and suspension formats improve administration for children and older patients
  • High-bioavailability amoxicillin profile supports common first-line pathways
  • Used across otitis, tonsillitis, sinusitis, LRTIs, and selected H. pylori protocols
ANCHORAGE 90 pediatric drops drug pack

ANCHORAGE 90 / ANCHORAGE 250

Dual-Action Coverage

Dosage Forms: ANCHORAGE 90 drops and ANCHORAGE 250 oral suspension.

Mechanism: Ampicillin offers broad-spectrum activity while Cloxacillin covers penicillinase-producing Staphylococci.

  • High-concentration drop profile supports low-volume neonatal and infant dosing
  • Dual-action empirical coverage where mixed or resistant organisms are possible
  • Supports severe pediatric infection pathways and staphylococcal-risk contexts
EFIXIM 125 oral suspension drug pack

EFIXIM 125

Pediatric Precision

Dosage Forms: EFIXIM 125 oral suspension.

Mechanism: Beta-lactam inhibition of transpeptidation via penicillin-binding proteins with bactericidal action.

  • Palatable suspension profile helps maintain pediatric treatment adherence
  • Built for accurate weight-aligned infant and child dose administration
  • Applied in RTIs, otitis media, UTIs, and pediatric GI infection coverage
CLAVIXIM 250 oral suspension drug pack

CLAVIXIM 250

Prodrug Advantage

Dosage Forms: CLAVIXIM 250 oral suspension.

Mechanism: Oral prodrug hydrolyzes to Ampicillin plus Sulbactam, extending spectrum through beta-lactamase inhibition.

  • Prodrug pharmacology improves oral absorption and tissue-level activity profile
  • Useful where beta-lactamase-producing organisms are part of the concern
  • Used in ENT infections, LRTIs, and abdominal infection treatment pathways
Clinical Matrix

Mechanism and Indication Matrix

Quick-reference clinical matrix for pharmacy operations, medical detailing, and institutional supply planning.

Brand Dosage Presentation Mechanism Snapshot Priority Indications
CLOVERAGE CLOVERAGE 625 and 1000 tablets; CLOVERAGE 228.5 and 457 suspensions Amoxicillin cell-wall inhibition + Clavulanic Acid beta-lactamase protection Sinusitis, otitis media, pneumonia, UTIs, skin and soft tissue infections
CLOVAXAN CLOVAXAN DT 125, DT 250, 500 tablets, and CLOVAXAN 125 suspension Selective inhibition of bacterial cell wall synthesis with bactericidal lysis Tonsillitis, pharyngitis, strep throat, LRTIs, acute bacterial sinusitis, pediatric infections
ANCHORAGE 90 / ANCHORAGE 250 ANCHORAGE 90 drops; ANCHORAGE 250 suspension Broad-spectrum Ampicillin plus penicillinase-resistant Cloxacillin dual activity Neonatal sepsis support, meningitis pathways, mixed infections, skin and soft tissue infections
EFIXIM 125 EFIXIM 125 suspension Beta-lactam blockade of peptidoglycan cross-linking through PBPs Upper and lower RTIs, otitis media, UTIs, and pediatric GI infections
CLAVIXIM 250 CLAVIXIM 250 suspension Mutual prodrug yielding Ampicillin and Sulbactam for extended-spectrum action ENT infections, chronic bronchitis exacerbation, LRTIs, abdominal infections

For prescribing decisions and institutional procurement, request full technical dossiers, label copies, and support documentation from Anchorage.

Anchorage laboratory quality team reviewing anti-infective formulations
Stewardship and Supply

Built for Prescribing Confidence and Dependable Supply Execution

Resistance-Aware Portfolio

Combination brands are positioned for scenarios where beta-lactamase protection and broader empirical confidence are needed.

Pediatric and Neonatal Fit

Dispersibles, suspensions, and neonatal drops improve dosing practicality for children and early-life treatment pathways.

Operational Reliability

Dosage Forms align with hospital formularies, pharmacy shelf realities, and distributor replenishment cycles.

Request Product Dossier

Need product dossiers, label references, and supply planning support?

Work with Anchorage for institution-ready product documentation, commercial planning, and technical partnership support for your care network.

Talk to Product Team